BRPI0508180A - 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste - Google Patents
1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso desteInfo
- Publication number
- BRPI0508180A BRPI0508180A BRPI0508180-7A BRPI0508180A BRPI0508180A BR PI0508180 A BRPI0508180 A BR PI0508180A BR PI0508180 A BRPI0508180 A BR PI0508180A BR PI0508180 A BRPI0508180 A BR PI0508180A
- Authority
- BR
- Brazil
- Prior art keywords
- oxadiazol
- modulators
- delta
- ones
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
1,3,4-OXADIAZOL-2-ONAS COMO MODULADORES DE PPAR DELTA E SEU USO DESTE. A presente invenção é direcionada a 1, 3, 4-oxadiazalonas, compostos de fórmula I e seus sais farmaceuticamente aceitáveis, estereoisómeros,, tautómeros, ou solvatos destes. Novos compostos incluem aqueles de fórmula I, nos quais os radicais são como definidos aqui. Os compostos desta invenção são moduladores de PPAR delta e portanto úteis como agentes farmacêuticos, especialmente para o tratamento de doenças de desmielinação e distúrbios do metabolismo de ácido graxo e utilização de glicose.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55842004P | 2004-04-01 | 2004-04-01 | |
PCT/US2005/010855 WO2005097763A2 (en) | 2004-04-01 | 2005-03-30 | 1,3,4-oxadiazol-2-ones as ppar delta |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0508180A true BRPI0508180A (pt) | 2007-08-07 |
Family
ID=34972960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0508180-7A BRPI0508180A (pt) | 2004-04-01 | 2005-03-30 | 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste |
Country Status (15)
Country | Link |
---|---|
US (2) | US7638539B2 (pt) |
EP (1) | EP1781648A2 (pt) |
JP (1) | JP4813461B2 (pt) |
CN (1) | CN1956984B (pt) |
AU (1) | AU2005230838A1 (pt) |
BR (1) | BRPI0508180A (pt) |
CA (1) | CA2561230A1 (pt) |
IL (1) | IL178166A0 (pt) |
MA (1) | MA28563B1 (pt) |
NO (1) | NO20064951L (pt) |
NZ (1) | NZ549823A (pt) |
RU (1) | RU2365589C2 (pt) |
SG (1) | SG151336A1 (pt) |
WO (1) | WO2005097763A2 (pt) |
ZA (1) | ZA200607852B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4813461B2 (ja) * | 2004-04-01 | 2011-11-09 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Pparデルタモジュレーターとしての1,3,4−オキサジアゾール−2−オン、および、それらの使用 |
CN100516065C (zh) * | 2004-04-01 | 2009-07-22 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
JP2007536343A (ja) | 2004-05-05 | 2007-12-13 | ノボ ノルディスク アクティーゼルスカブ | Pparアゴニストとしてのフェノキシ酢酸誘導体 |
EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
EA015717B1 (ru) | 2005-12-22 | 2011-10-31 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
EP1999098A2 (en) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Compounds that modulate ppar activity, their preparation and use |
CA2774999A1 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
BRPI1107312B1 (pt) * | 2011-11-25 | 2021-09-08 | Universidade Federal De Santa Catarina | Composto de acil-hidrazona |
US9487493B2 (en) | 2013-09-09 | 2016-11-08 | Vtv Therapeutics Llc | Use of a PPAR-delta agonist for treating muscle atrophy |
KR101715127B1 (ko) * | 2015-10-30 | 2017-03-15 | 한국과학기술연구원 | 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체 |
CN114195777B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114195786B (zh) * | 2020-09-18 | 2023-08-22 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
US4895953A (en) * | 1987-09-30 | 1990-01-23 | American Home Products Corporation | 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US4826990A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
AU770870B2 (en) * | 1999-06-18 | 2004-03-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
WO2001017994A1 (en) * | 1999-09-08 | 2001-03-15 | Glaxo Group Limited | Oxazole ppar antagonists |
JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
CN100516065C (zh) * | 2004-04-01 | 2009-07-22 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
JP4813461B2 (ja) * | 2004-04-01 | 2011-11-09 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Pparデルタモジュレーターとしての1,3,4−オキサジアゾール−2−オン、および、それらの使用 |
-
2005
- 2005-03-30 JP JP2007506541A patent/JP4813461B2/ja not_active Expired - Fee Related
- 2005-03-30 CN CN200580017003.5A patent/CN1956984B/zh not_active Expired - Fee Related
- 2005-03-30 CA CA002561230A patent/CA2561230A1/en not_active Abandoned
- 2005-03-30 NZ NZ549823A patent/NZ549823A/en unknown
- 2005-03-30 AU AU2005230838A patent/AU2005230838A1/en not_active Abandoned
- 2005-03-30 EP EP05767047A patent/EP1781648A2/en not_active Withdrawn
- 2005-03-30 SG SG200902266-6A patent/SG151336A1/en unknown
- 2005-03-30 BR BRPI0508180-7A patent/BRPI0508180A/pt not_active IP Right Cessation
- 2005-03-30 RU RU2006138494/04A patent/RU2365589C2/ru not_active IP Right Cessation
- 2005-03-30 WO PCT/US2005/010855 patent/WO2005097763A2/en active Application Filing
-
2006
- 2006-09-18 IL IL178166A patent/IL178166A0/en unknown
- 2006-09-19 ZA ZA200607852A patent/ZA200607852B/en unknown
- 2006-09-27 US US11/535,764 patent/US7638539B2/en not_active Expired - Fee Related
- 2006-10-30 NO NO20064951A patent/NO20064951L/no not_active Application Discontinuation
- 2006-10-31 MA MA29429A patent/MA28563B1/fr unknown
-
2009
- 2009-07-20 US US12/505,881 patent/US7872032B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7638539B2 (en) | 2009-12-29 |
SG151336A1 (en) | 2009-04-30 |
US7872032B2 (en) | 2011-01-18 |
RU2365589C2 (ru) | 2009-08-27 |
JP2007531764A (ja) | 2007-11-08 |
WO2005097763A2 (en) | 2005-10-20 |
JP4813461B2 (ja) | 2011-11-09 |
AU2005230838A1 (en) | 2005-10-20 |
CN1956984A (zh) | 2007-05-02 |
US20090275621A1 (en) | 2009-11-05 |
EP1781648A2 (en) | 2007-05-09 |
RU2006138494A (ru) | 2008-05-10 |
US20070099964A1 (en) | 2007-05-03 |
MA28563B1 (fr) | 2007-04-03 |
CN1956984B (zh) | 2010-06-09 |
WO2005097763A3 (en) | 2005-12-15 |
NZ549823A (en) | 2009-12-24 |
CA2561230A1 (en) | 2005-10-20 |
ZA200607852B (en) | 2008-07-30 |
IL178166A0 (en) | 2006-12-31 |
NO20064951L (no) | 2006-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0508180A (pt) | 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste | |
US20170049781A1 (en) | Hsp90 inhibitor combinations | |
BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
BRPI0512252A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto | |
BRPI0519774A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, formulaÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, mÉtodo de tratamento de uma doenÇa em que inibiÇço da atividade de um membro da famÍlia mapeg É desejada e/ou necessÁria, produto combinado, e, processo para a preparaÇço de um composto | |
BR0311591A (pt) | 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6 | |
BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
BRPI0718714B8 (pt) | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende | |
CO6361928A2 (es) | Modulares de aril metil benzoquinazolinona alostericos positivos del receptor m1 | |
BRPI1015367B8 (pt) | derivados imidazo[2,1-b][1,3,4]tiadiazol | |
BR0116323A (pt) | Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
BR0316169A (pt) | Derivados de indolil pirazinona úteis para tratamento de distúrbios e doenças hiperproliferativos associados com angiogênese | |
BR0308816A (pt) | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas | |
BRPI0820112B8 (pt) | derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento | |
SE0402735D0 (sv) | Novel compounds | |
BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
EA200870360A1 (ru) | Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине | |
BRPI0519287A2 (pt) | derivados de amida |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: AVENTIS PHARMACEUTICALS, INC. (US) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |